Mark D Scott

USPTO Granted Patents = 11 (Patent Applications = 3)

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 2.8

ph-index = 2

Forward Citations = 14(Granted Patents)

Location History:

Vancouver, CA (2011)
Surrey, CA (2011 - 2021)

Company Filing History:

9 out of 33

Canadian Blood Services

patents

1 out of 1

Canadian Bllood Services

patent

1 out of 1

Canadian Blood Cervices

patent

Years Active: 2011-2021

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11007221 - Acellular pro-inflammatory compositions, process for making same and methods of using same (2021-05-18),

2. 10561685 - Combination therapy of acellular pro-tolerogenic and pro-inflammatory preparations for modulating the immune system (2020-02-18),

3. 10188681 - Method for inducing immune tolerance using non-proliferative polymer-modified allogeneic leukocytes (2019-01-29),

4. 10039788 - Acellular pro-tolerogenic compositions for treatment/prevention of graft rejection (2018-08-07),

5. 10039787 - Acellular pro-tolerogenic compositions for the treatment/prevention of auto-immune diseases (2018-08-07),

6. 10039786 - Acellular pro-tolerogenic compositions and process for making same (2018-08-07),

7. 9498496 - Method for inducing immune tolerance using viable polymer-modified allogeneic leukocytes (2016-11-22),

8. 8454934 - High molecular weight chelation structure (2013-06-04),

9. 8067151 - Cold storage of pegylated platelets at about or below 0° C. (2011-11-29),

10. 8048620 - Method for enhancing the detection of contamination in a cellular blood product by covalently binding a hydrophilic polymer to the cell membrane (2011-11-01),

11. 7964339 - Cold storage of modified platelets (2011-06-21),

Title: Mark D Scott: Innovator in Acellular Therapies

Introduction

Mark D Scott is a prominent inventor based in Surrey, Canada. He has made significant contributions to the field of immunology through his innovative patents. With a total of 11 patents to his name, Scott has focused on developing acellular-based therapies aimed at modulating immune responses.

Latest Patents

Among his latest patents is the invention titled "Acellular pro-inflammatory compositions, process for making same and methods of using same." This invention relates to acellular-based therapies designed to decrease the level of regulatory T cells (Treg) and increase the level of pro-inflammatory T cells (Th17) to favor immune stimulation. The therapeutic effects are achieved by contacting an allogeneic leukocyte population with another leukocyte population, allowing for the isolation of acellular components.

Another notable patent is "Combination therapy of acellular pro-tolerogenic and pro-inflammatory preparations for modulating the immune system." This disclosure focuses on cellular-based therapies that modulate the levels of Treg and pro-inflammatory T cells (Th17/Th1). The therapy involves administering a combination of at least one acellular pro-tolerogenic preparation and one acellular pro-inflammatory preparation sequentially.

Career Highlights

Mark D Scott has worked with Canadian Blood Services, where he has contributed to advancements in blood and immune therapies. His work has been instrumental in developing innovative solutions that enhance patient care and treatment outcomes.

Collaborations

Scott has collaborated with notable colleagues, including Duncheng Wang and Wendy M Toyofuku, who have contributed to his research and development efforts.

Conclusion

Mark D Scott is a distinguished inventor whose work in acellular therapies has the potential to transform immunological treatments. His innovative patents reflect a commitment to advancing medical science and improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.